GAP & NPP Initiatives 3 Real- World Execution by GNH USA Welcome to this strategic overview of how GNH USA delivers market access solutions through proven Global Access Programme (GAP) and Named Patient Programme (NPP) initiatives. Today, we'll demonstrate our practical execution capabilities and share authentic case examples that showcase how we help pharmaceutical companies navigate complex international markets. Our objective is straightforward: to illustrate how these initiatives translate theory into tangible business outcomes, enabling faster market entry, informed pricing strategies, and early revenue generation whilst maintaining full regulatory compliance.
STRATEGIC OVERVIEW Understanding GAP and NPP
Market Access Solutions That Deliver Results What Are These Initiatives? The Global Access Programme (GAP) and Named Patient Programme (NPP) are strategic market access mechanisms designed to bridge the gap between product availability and full commercial registration. Rather than waiting years for complete regulatory approval, these programmes enable pharmaceutical companies to establish market presence, gather critical real-world data, and generate revenue streams. GAP focuses on creating structured pathways for products to reach multiple international markets through established regulatory frameworks. NPP addresses specific patient needs by providing access to medicines not yet commercially available in their country, creating a compassionate access route that simultaneously builds market intelligence. These aren't theoretical constructs4they're practical business tools that transform market entry timelines from years to months.
V ALUE PROPOSITION Core Benefits of GAP & NPP Delivered by GNH USA Our execution of GAP and NPP initiatives delivers three fundamental advantages that directly impact your market access strategy and commercial outcomes. Real-World Market Intelligence Access genuine pricing data, prescriber behaviour patterns, and market dynamics before full product launch. This intelligence informs optimal pricing strategies, identifies key opinion leaders, and validates market assumptions with actual transactional data rather than theoretical projections. Established Import Infrastructure Leverage our network of qualified import partners who navigate the complex legal and regulatory requirements in target markets. From customs documentation to pharmacovigilance reporting, our partners handle the administrative burden, ensuring compliance whilst accelerating time-to-market. Pre-Registration Revenue Generation Begin generating revenue streams months or years before achieving full product registration. These early sales offset development costs, demonstrate commercial viability to stakeholders, and establish your brand presence with healthcare providers ahead of competitors.
PROVEN EXECUTION Real Case Examples
GAP & NPP in Action Our track record speaks through actual implementations. Here are two anonymised cases demonstrating how we've transformed market access challenges into commercial opportunities. Case A: Oncology Specialty Product 3 Central European Market Challenge: A mid-sized pharmaceutical company faced a 24-month registration timeline for their innovative oncology treatment in a key Central European market. Competitors were already establishing market presence. GNH USA Solution: We implemented a structured NPP pathway through our established import partner network. Within 90 days, the product was accessible to qualified oncologists for named patient requests. Outcomes: The client gathered real-world efficacy data from 47 patients over 18 months, identified 12 key prescribers who became advocates, and generated $340,000 in revenue before full registration4directly informing their launch pricing strategy with actual willingness-to-pay data. Case B: Rare Disease Therapy 3 Multiple APAC Markets Challenge: A biotech company needed to establish presence across five Asia-Pacific markets for a rare disease treatment, but lacked local regulatory expertise and faced 36+ month registration timelines. GNH USA Solution: We deployed a coordinated GAP strategy across all five markets simultaneously, utilising our pre-qualified import infrastructure and handling all regulatory documentation through local partners. Outcomes: Market access achieved in all five countries within six months. The client collected comparative pricing intelligence across markets, identified optimal entry pricing 15% higher than initially projected, and generated $1.2M in aggregate revenue whilst full registrations progressed. Three markets subsequently became priority launch targets based on GAP performance data.
Strategic Value for LUPIN USA & Next Steps For LUPIN USA, GAP and NPP initiatives represent a strategic accelerator for your international expansion plans. The value proposition is compelling: reduced time-to-market by 12-18 months, significantly lower regulatory risk through established pathways, and early revenue opportunities that improve project economics whilst building market intelligence. Rather than waiting for full registration in each target market, you can establish presence, gather critical real-world data, and begin revenue generation within quarters, not years. Our proven import infrastructure removes the burden of navigating unfamiliar regulatory landscapes, whilst our network delivers the local expertise required for compliant execution.
- Immediate Portfolio assessment call to identify priority products and target markets
- Short-term Pilot programme design for 1-2 products in selected markets
- Ongoing Scale proven pathways across broader portfolio and geographies We invite LUPIN USA to explore a pilot opportunity that demonstrates these capabilities with minimal commitment. Let's discuss which products and markets would benefit most from immediate GAP or NPP implementation.